Mammalian TNF- &agr; convertase
US6531290B2 · kind B2 · utility
5Cited by
0References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 17, 2001 |
| Grant date | Mar 11, 2003 |
| Priority date | — |
| Expiry date | Oct 17, 2021 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/96486
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention provides isolated human and bovine TNF-&agr; convertases, nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-&agr;. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-&agr; convertases, and for identifying nucleic acids encoding such convertases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.